Boxer Capital, LLC Buys Odonate Therapeutics Inc, Ionis Pharmaceuticals Inc, WAVE Life Sciences, Sells Clovis Oncology Inc, The Medicines Co, Incyte Corp

• New Purchases: ODT, IONS, WVE, RIGL, CNCE, GTXI, ARDM, RGLS,
• Added Positions: MRTX, CBAY, KURA, AVXS, MGNX, SNSS, PTCT,
• Reduced Positions: MDCO, ESPR, AQXP, SNDX,
• Sold Out: CLVS, INCY, PBYI, SBBP, SGEN, EIGR, ONTX,

For the details of Boxer Capital, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Boxer+Capital%2C+LLC

1. AveXis Inc (AVXS) - 825,000 shares, 16.77% of the total portfolio. Shares added by 3.13%
2. Odonate Therapeutics Inc (ODT) - 2,726,938 shares, 12.52% of the total portfolio. New Position
3. BeiGene Ltd (BGNE) - 600,000 shares, 10.77% of the total portfolio.
4. Esperion Therapeutics Inc (ESPR) - 800,000 shares, 9.68% of the total portfolio. Shares reduced by 20%
5. Macrogenics Inc (MGNX) - 2,200,000 shares, 7.68% of the total portfolio. Shares added by 4.02%

Boxer Capital, LLC initiated holding in Odonate Therapeutics Inc. The purchase prices were between $22.67 and $25, with an estimated average price of $23.63. The stock is now traded at around $22.29. The impact to a portfolio due to this purchase was 12.52%. The holding were 2,726,938 shares as of 2017-12-31.

Boxer Capital, LLC initiated holding in Ionis Pharmaceuticals Inc. The purchase prices were between $50.3 and $64.39, with an estimated average price of $54.83. The stock is now traded at around $48.99. The impact to a portfolio due to this purchase was 4.16%. The holding were 450,000 shares as of 2017-12-31.

Boxer Capital, LLC initiated holding in WAVE Life Sciences Ltd. The purchase prices were between $21.8 and $39.35, with an estimated average price of $29.02. The stock is now traded at around $39.85. The impact to a portfolio due to this purchase was 3.55%. The holding were 550,000 shares as of 2017-12-31.

Boxer Capital, LLC initiated holding in Rigel Pharmaceuticals Inc. The purchase prices were between $3.23 and $4.3, with an estimated average price of $3.8. The stock is now traded at around $3.75. The impact to a portfolio due to this purchase was 2.24%. The holding were 3,140,000 shares as of 2017-12-31.

Boxer Capital, LLC initiated holding in Concert Pharmaceuticals Inc. The purchase prices were between $13.96 and $29.05, with an estimated average price of $20.1. The stock is now traded at around $22.75. The impact to a portfolio due to this purchase was 1.9%. The holding were 400,000 shares as of 2017-12-31.

Boxer Capital, LLC initiated holding in GTx Inc. The purchase prices were between $7.51 and $13.1, with an estimated average price of $10.3. The stock is now traded at around $17.97. The impact to a portfolio due to this purchase was 1.32%. The holding were 565,291 shares as of 2017-12-31.

Boxer Capital, LLC added to a holding in Mirati Therapeutics Inc by 32.23%. The purchase prices were between $12.65 and $19, with an estimated average price of $15.49. The stock is now traded at around $32.55. The impact to a portfolio due to this purchase was 1.12%. The holding were 1,372,510 shares as of 2017-12-31.

Boxer Capital, LLC added to a holding in CymaBay Therapeutics Inc by 138.35%. The purchase prices were between $7.67 and $9.31, with an estimated average price of $8.54. The stock is now traded at around $12.37. The impact to a portfolio due to this purchase was 0.99%. The holding were 1,012,986 shares as of 2017-12-31.

Boxer Capital, LLC added to a holding in Kura Oncology Inc by 58.42%. The purchase prices were between $13.5 and $16.65, with an estimated average price of $14.72. The stock is now traded at around $19.40. The impact to a portfolio due to this purchase was 0.87%. The holding were 844,789 shares as of 2017-12-31.

Boxer Capital, LLC added to a holding in Sunesis Pharmaceuticals Inc by 29.27%. The purchase prices were between $1.85 and $3.69, with an estimated average price of $2.67. The stock is now traded at around $2.95. The impact to a portfolio due to this purchase was 0.2%. The holding were 1,325,000 shares as of 2017-12-31.

Boxer Capital, LLC sold out a holding in Clovis Oncology Inc. The sale prices were between $57.69 and $84.58, with an estimated average price of $70.03.

Boxer Capital, LLC sold out a holding in Incyte Corp. The sale prices were between $93.56 and $116.6, with an estimated average price of $104.61.

Boxer Capital, LLC sold out a holding in Puma Biotechnology Inc. The sale prices were between $93.85 and $132.45, with an estimated average price of $112.

Boxer Capital, LLC sold out a holding in Strongbridge Biopharma PLC. The sale prices were between $5.35 and $7.5, with an estimated average price of $6.24.

Boxer Capital, LLC sold out a holding in Seattle Genetics Inc. The sale prices were between $51.82 and $64.08, with an estimated average price of $58.37.

Boxer Capital, LLC sold out a holding in Eiger BioPharmaceuticals Inc. The sale prices were between $10.5 and $14.15, with an estimated average price of $11.91.

Boxer Capital, LLC reduced to a holding in The Medicines Co by 38.27%. The sale prices were between $26 and $38.3, with an estimated average price of $30.83. The stock is now traded at around $33.16. The impact to a portfolio due to this sale was -4.42%. Boxer Capital, LLC still held 750,000 shares as of 2017-12-31.

Boxer Capital, LLC reduced to a holding in Aquinox Pharmaceuticals Inc by 40.48%. The sale prices were between $10.08 and $14.32, with an estimated average price of $11.73. The stock is now traded at around $14.99. The impact to a portfolio due to this sale was -0.75%. Boxer Capital, LLC still held 312,500 shares as of 2017-12-31.

Boxer Capital, LLC reduced to a holding in Syndax Pharmaceuticals Inc by 57.31%. The sale prices were between $7.8 and $12.94, with an estimated average price of $9.91. The stock is now traded at around $14.82. The impact to a portfolio due to this sale was -0.47%. Boxer Capital, LLC still held 100,000 shares as of 2017-12-31.